Bifunctional Tau-Targeting Compounds for E3 Ligase Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative disorders associated with Tau protein aggregation, such as tauopathies, have proven ineffective in clinical trials despite promising pre-clinical data, highlighting the need for effective therapies that can modulate targeted ubiquitination and degradation of Tau protein.
Innovation Solution
Development of heterobifunctional compounds that recruit Tau protein to E3 ubiquitin ligases for targeted ubiquitination and subsequent proteasomal degradation, utilizing moieties that bind both Tau protein and E3 ubiquitin ligases, such as cereblon, IAP, or Von Hippel-Lindau E3 ubiquitin ligases, to facilitate the degradation of Tau protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecules are used to target protein-protein interactions, then therapeutic specificity can be achieved, but binding affinity and stability are insufficient due to large contact surfaces and shallow grooves
Solution Approach 1:
The patent combines a Tau-binding moiety and an E3 ligase-binding moiety into a single heterobifunctional compound, merging two separate binding functions to achieve both specificity and enhanced stability in targeting Tau protein for degradation
Solution Approach 2:
The patent introduces E3 ubiquitin ligases as intermediary proteins that facilitate the degradation of Tau protein. The heterobifunctional compound acts as a mediator that brings Tau and E3 ligase together, enabling targeted ubiquitination and degradation without requiring direct stable binding between the small molecule and Tau
2Productivity
If current treatments are used for tauopathies, then clinical trials can be conducted, but therapeutic effectiveness is insufficient despite promising pre-clinical data
Solution Approach 1:
Instead of trying to stabilize or inhibit Tau aggregation directly, the patent inverts the approach by promoting targeted degradation of Tau protein through the ubiquitin-proteasome pathway, using heterobifunctional compounds to recruit E3 ligases to Tau for ubiquitination and subsequent degradation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively reduce Tau protein levels in cells and tissues, offering potential therapeutic benefits for treating or ameliorating neurodegenerative diseases by modulating Tau aggregation and degradation.
Implementation Method 1
The bifunctional compounds are useful as modulators of targeted ubiquitination of Tau protein
Implementation Method 2
which is then degraded and/or inhibited
Data Source
AI summary
The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.